Patents by Inventor Erik WILKER

Erik WILKER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KINASE INHIBITOR COMBINATIONS FOR CANCER TREATMENT
    Publication number: 20240024324
    Abstract: A combination includes 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, an inhibitor of MEK kinase, and as an optional third inhibitor, an inhibitor of EGFR. The combination is useful for the treatment of cancer. Another combination includes 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifloromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, and an inhibitor of EGFR.
    Type: Application
    Filed: November 15, 2021
    Publication date: January 25, 2024
    Inventors: Anderson Clark, Andreas Machl, Bayard Huck, Erik Wilker, Remigiusz Kaleta
  • TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS
    Publication number: 20210252011
    Abstract: The present disclosure relates to methods of treating glioblastoma by administering to a patient in need thereof a FASN inhibitor.
    Type: Application
    Filed: October 25, 2018
    Publication date: August 19, 2021
    Inventors: Wei LU, Matthew W. MARTIN, Erik WILKER, Howard FINE
  • Combinations of cancer therapeutics
    Patent number: 9980966
    Abstract: The invention relates to combinations of 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, and an inhibitor of Her2, and the use of such combinations for the treatment of cancer.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: May 29, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Erik Wilker, Andreas Machl, Remigiusz Kaleta
  • COMBINATIONS OF CANCER THERAPEUTICS
    Publication number: 20170100402
    Abstract: The invention relates to combinations of 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, and an inhibitor of Her2, and the use of such combinations for the treatment of cancer.
    Type: Application
    Filed: March 9, 2015
    Publication date: April 13, 2017
    Inventors: Bayard R. HUCK, Erik WILKER, Andreas MACHL, Remigiusz KALETA